CSIMarket
 
Calithera Biosciences Inc   (CALA)
Other Ticker:  
 

Calithera Biosciences Inc

Business Description


Calithera Biosciences Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company was founded in 2010 and is headquartered in South San Francisco, California.

Calithera*s primary focus is on discovering and developing novel therapies that target the metabolic pathways in cancer cells. By understanding the specific metabolic alterations that occur in cancer cells, the company aims to develop drugs that selectively target these pathways, leading to the inhibition of tumor growth and potentially providing new treatment options for patients.

The company*s lead product candidate is CB-839, an orally administered inhibitor of glutaminase, which is an enzyme that plays a key role in cancer cell metabolism. CB-839 is currently being evaluated in multiple clinical trials for various types of solid tumors, including renal cell carcinoma, triple-negative breast cancer, and pancreatic cancer. Preliminary data from these trials have shown promising anti-tumor activity and safety profile.

Calithera also has a collaborative partnership with Incyte Corporation, a global biopharmaceutical company, to develop and commercialize CB-839 in combination with Incyte*s investigational treatment, capmatinib, for the treatment of patients with solid tumors. This collaboration provides Calithera with additional resources and expertise to further advance its drug candidates.

In addition to its lead product candidate, Calithera has a pipeline of other small molecule inhibitors targeting metabolic pathways. These include CB-1158, an orally administered inhibitor of arginase, which is being evaluated in clinical trials for the treatment of various solid tumors and hematological malignancies. The company is also exploring other metabolic targets, such as IDO1 and ASCT2, with the aim of developing innovative therapies for patients with limited treatment options.

Calithera has a team of experienced scientists and researchers who specialize in cancer biology, drug discovery, and drug development. They work closely with academic institutions and other industry partners to leverage the latest advancements in science and technology to drive the development of novel therapies.

Overall, Calithera Biosciences Inc. is dedicated to developing innovative therapies that target metabolic pathways in cancer cells. Through their rigorous research and clinical development programs, the company aims to make a meaningful impact on the lives of patients with cancer and other diseases.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com